Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Supplier Guide: How to Evaluate Quality (2026)
articleRetatrutide is investigational and only accessible through the research-chemical gray market. This guide covers the five criteria that distinguish a Tier 1 retatrutide supplier from lower-quality vendors: named-lab COA verification, Finnrick Analytics per-compound grades, US warehouse status, batch traceability, and community validation history.
LillyDirect Zepbound: Complete Guide to Self-Pay Vials (2026)
articleEverything you need to know about ordering Zepbound through LillyDirect: pricing by dose tier, eligibility, pharmacy partners, and the 5-step ordering process.
Vendor Safety Methodology: How GLP3Planner Evaluates Peptide Sourcing
referenceEditorial methodology for vendor evaluation: 40 active US peptide research-chemical vendors assessed across six criteria, third-party verified against Finnrick Analytics and Janoshik Analytical, with the market reshuffle context that changed the trust calculus in 2025-2026.